Email Updates

You are here

Home

PURPOSE 3/ HPTN 102

Status
Planned
Phase
Open Label
Objective

A Randomized, Open-Label Study of Acceptability and Use of Lenacapavir vs TDF/FTC Among US Women

Study is planned as of Dec 2021 shown here; this upcoming study was also mentioned at HPTN 2022

Last updated June 10, 2022

 

Prevention Option(s)
PrEP
Study Design
Randomized
Open label
Arms and Assigned Interventions
Products
Lenacapavir
ARMs
Experimental
Products
TDF/FTC (Truvada)
ARMs
Active Comparator
Population
Women